EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma
Tumor immune evasion is a lineament of cancer. Endothelial monocyte activating polypeptide-II (EMAP II) has been assumed to impact tumor immune escape significantly. EMAP II was first reported in the murine methylcholanthrene A-induced fibrosarcoma supernatant and identified as a tumor-derived cytok...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2022/7219207 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563475445972992 |
|---|---|
| author | Manal Mohamed Saber |
| author_facet | Manal Mohamed Saber |
| author_sort | Manal Mohamed Saber |
| collection | DOAJ |
| description | Tumor immune evasion is a lineament of cancer. Endothelial monocyte activating polypeptide-II (EMAP II) has been assumed to impact tumor immune escape significantly. EMAP II was first reported in the murine methylcholanthrene A-induced fibrosarcoma supernatant and identified as a tumor-derived cytokine. This study evaluated EMAP II expression in peripheral blood cells and its association with treatment outcome, lactate dehydrogenase (LDH) levels, and clinical criteria in non-Hodgkin’s lymphoma (NHL) patients. EMAP II expression on different blood cells obtained from the peripheral blood of 80 NHL patients was evaluated by two-color flow cytometry. The study reported that EMAP II expression was significantly increased in peripheral blood cells in patients with NHL compared to normal volunteers (P<0.001). Additionally, EMAP II expression levels on blood cells decreased in complete remission (CR) while they increased in relapse. This study showed coexpression of EMAP II and CD36 on peripheral lymphocytes in NHL patients but not in healthy controls (P<0.001). EMAP II expression on blood cells was associated with increased serum LDH levels. Furthermore, the percentages of EMAP II+/CD36+ peripheral lymphocytes were significantly higher in relapse than in CR and healthy controls. Analyses revealed that higher percentages of EMAP II+CD36+ cells were positively correlated with hepatomegaly, splenomegaly, and an advanced (intermediate and high risk) NHL stage. The results assume that EMAP II might be involved in NHL development and pathogenesis. |
| format | Article |
| id | doaj-art-14ffe9982db042d188dd29122c22f474 |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-14ffe9982db042d188dd29122c22f4742025-02-03T01:19:59ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/7219207EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin LymphomaManal Mohamed Saber0Department of Clinical PathologyTumor immune evasion is a lineament of cancer. Endothelial monocyte activating polypeptide-II (EMAP II) has been assumed to impact tumor immune escape significantly. EMAP II was first reported in the murine methylcholanthrene A-induced fibrosarcoma supernatant and identified as a tumor-derived cytokine. This study evaluated EMAP II expression in peripheral blood cells and its association with treatment outcome, lactate dehydrogenase (LDH) levels, and clinical criteria in non-Hodgkin’s lymphoma (NHL) patients. EMAP II expression on different blood cells obtained from the peripheral blood of 80 NHL patients was evaluated by two-color flow cytometry. The study reported that EMAP II expression was significantly increased in peripheral blood cells in patients with NHL compared to normal volunteers (P<0.001). Additionally, EMAP II expression levels on blood cells decreased in complete remission (CR) while they increased in relapse. This study showed coexpression of EMAP II and CD36 on peripheral lymphocytes in NHL patients but not in healthy controls (P<0.001). EMAP II expression on blood cells was associated with increased serum LDH levels. Furthermore, the percentages of EMAP II+/CD36+ peripheral lymphocytes were significantly higher in relapse than in CR and healthy controls. Analyses revealed that higher percentages of EMAP II+CD36+ cells were positively correlated with hepatomegaly, splenomegaly, and an advanced (intermediate and high risk) NHL stage. The results assume that EMAP II might be involved in NHL development and pathogenesis.http://dx.doi.org/10.1155/2022/7219207 |
| spellingShingle | Manal Mohamed Saber EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma Journal of Immunology Research |
| title | EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma |
| title_full | EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma |
| title_fullStr | EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma |
| title_full_unstemmed | EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma |
| title_short | EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma |
| title_sort | emap ii expression is increased on peripheral blood cells from non hodgkin lymphoma |
| url | http://dx.doi.org/10.1155/2022/7219207 |
| work_keys_str_mv | AT manalmohamedsaber emapiiexpressionisincreasedonperipheralbloodcellsfromnonhodgkinlymphoma |